LSUHSC Minority Based Community Clinical Oncology

从1994年到2000年，路易斯安那州立大学是一个资助的以少数民族为基础的社区临床肿瘤学项目（MB CCOP）。去年的申请获得了有利的审查，但没有获得资助。本次提交是一份修改后的申请，解决了去年提交的总结声明中提出的问题，扩展了之前对我们项目的描述，并更新了我们的现状。该提案表明，我们将继续致力于路易斯安那州南部少数族裔和服务不足人群的癌症控制。根据路易斯安那州的癌症发病率，癌症死亡率高于预期。这在一定程度上是由于诊断阶段较晚，这在服务不足和少数民族人群中似乎更为普遍。贫困人口可以通过全州范围内的医院系统获得医疗服务，因此障碍可能更多是信息上的，而不是物质或经济上的。外联是我们所需要的，也是我们的力量所在。虽然我们在治疗方面取得了成功，但我们在少数人参加癌症预防研究方面的成果，以及由此产生的推广工作，将对癌症控制产生更大的影响。在STAR项目的第一年，我们招收了19%的少数族裔女性，大约是全国研究的十倍。在此之前，我们在PCPT上取得了类似的成功，我们的少数族裔入学率是全国研究的四倍。当SELECT在9月开放时，我们相信我们所建立的外展努力将导致大量非裔美国人加入这项研究。我们已经扭转了治疗和癌症控制登记人数的下降趋势，并提出通过以下目标继续取得成功：(1)继续我们有能力的数据管理团队的合作努力，(2)增加STAR的参与并增加SELECT，(3)继续只开放那些可能实现累积的研究，(4)增加医生对MB CCOP试验支持的激励，(5)仔细权衡扩展机会，以保持我们对路易斯安那州少数民族和服务不足人群的扩展目标的关注。国家癌症研究所的财政支持将保证我们继续取得成功。

LSU was a funded Minority-Based Community Clinical Oncology Program (MB CCOP) from 1994 to 2000. Last year's submission received a favorable review but not funding. This submission is an amended application which addresses the points raised in the Summary Statement of last years submission, expands on previous descriptions of our program, and updates our current status. The proposal demonstrates our continued commitment to efforts to cancer control in the minority and under-served populations of southern Louisiana. Cancer mortality is greater than expected based on cancer incidence in Louisiana. This, in part, is due to advanced stage at diagnosis which appears to be greater among underserved and minority population. Access to care is available through a statewide hospital system for indigent populations so the barriers may be more informational than physical or financial. Outreach is what is needed and that is our strength. Although we are successful in treatment efforts, our results in minority enrollment onto cancer prevention studies and the outreach efforts which produces those enrollments will have a greater impact in cancer control. During our first year of the STAR program we enrolled 19% minority women which was roughly ten times that of the national study. This follows a similar success we enjoyed with PCPT where we had four times higher minority enrollment percentage than did the national study. When SELECT opens in September, we are confident the outreach efforts we have established will result in large numbers of African-American men joining the study. We have reversed declines in treatment and cancer control enrollments and propose continued success via the following goals: (1) Continue the collaborative efforts of our capable data management team, (2) Increase participation in STAR and add SELECT, (3) Continue to open only those studies likely to achieve accrual, (4) Increase physician incentives for support of the MB CCOP trials, (5) Carefully weigh expansion opportunities to remain focused on our goal of outreach to minority and under-served populations of Louisiana. The financial support of the National Cancer Institute will assure our continued success.